erdafitinib,cetrelimab,enfortumab,Pembrolizumab,cisplatin,carboplatin,gemcitabine,Atezolizumab
janssen,Astellas,Merck,Seagen,Roche
['urothelial']
 beautifully summarizes 3 oral abstracts highlighting the difficulties in cross trial comparisons because of the different patient population of metastatic #urothelialcarcinoma that enroll in these trials #asco23 
Medical Oncologist, Investigator, Chief, #BladderCancer Section, #GenitourinaryTumors, NCI, NIH #RareTumors #PatientAdvocate, Latina. Views are my own